128 related articles for article (PubMed ID: 7798277)
1. Evidence for the uptake of a vitamin D analogue (OCT) by a human carcinoma and its effect of suppressing the transcription of parathyroid hormone-related peptide gene in vivo.
Endo K; Ichikawa F; Uchiyama Y; Katsumata K; Ohkawa H; Kumaki K; Ogata E; Ikeda K
J Biol Chem; 1994 Dec; 269(51):32693-9. PubMed ID: 7798277
[TBL] [Abstract][Full Text] [Related]
2. Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
Endo K; Katsumata K; Iguchi H; Kubodera N; Teramoto T; Ikeda K; Fujita T; Ogata E
J Bone Miner Res; 1998 Sep; 13(9):1378-83. PubMed ID: 9738509
[TBL] [Abstract][Full Text] [Related]
3. 22-Oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected T cells.
Inoue D; Matsumoto T; Ogata E; Ikeda K
J Biol Chem; 1993 Aug; 268(22):16730-6. PubMed ID: 8393873
[TBL] [Abstract][Full Text] [Related]
4. The noncalcemic vitamin D analogues EB1089 and 22-oxacalcitriol interact with the vitamin D receptor and suppress parathyroid hormone-related peptide gene expression.
Falzon M
Mol Cell Endocrinol; 1997 Mar; 127(1):99-108. PubMed ID: 9099905
[TBL] [Abstract][Full Text] [Related]
5. 1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion.
Endo K; Katsumata K; Hirata M; Masaki T; Kubodera N; Nakamura T; Ikeda K; Ogata E
J Bone Miner Res; 2000 Jan; 15(1):175-81. PubMed ID: 10646127
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia.
Yu J; Papavasiliou V; Rhim J; Goltzman D; Kremer R
Anticancer Drugs; 1995 Feb; 6(1):101-8. PubMed ID: 7756673
[TBL] [Abstract][Full Text] [Related]
7. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
Haq M; Kremer R; Goltzman D; Rabbani SA
J Clin Invest; 1993 Jun; 91(6):2416-22. PubMed ID: 8514854
[TBL] [Abstract][Full Text] [Related]
8. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia.
Abe J; Nakano T; Nishii Y; Matsumoto T; Ogata E; Ikeda K
Endocrinology; 1991 Aug; 129(2):832-7. PubMed ID: 1855478
[TBL] [Abstract][Full Text] [Related]
9. Regulation of renal parathyroid hormone receptor expression by 1, 25-dihydroxyvitamin D3 and retinoic acid.
Sneddon WB; Barry EL; Coutermarsh BA; Gesek FA; Liu F; Friedman PA
Cell Physiol Biochem; 1998; 8(5):261-77. PubMed ID: 9792954
[TBL] [Abstract][Full Text] [Related]
10. In vivo evidence for progressive activation of parathyroid hormone-related peptide gene transcription with tumor growth and stimulation of osteoblastic bone formation at an early stage of humoral hypercalcemia of cancer.
Yamato H; Nagai Y; Inoue D; Ohnishi Y; Ueyama Y; Ohno H; Matsumoto T; Ogata E; Ikeda K
J Bone Miner Res; 1995 Jan; 10(1):36-44. PubMed ID: 7747629
[TBL] [Abstract][Full Text] [Related]
11. The noncalcemic vitamin D analogs EB1089 and 22-oxacalcitriol suppress serum-induced parathyroid hormone-related peptide gene expression in a lung cancer cell line.
Falzon M; Zong J
Endocrinology; 1998 Mar; 139(3):1046-53. PubMed ID: 9492037
[TBL] [Abstract][Full Text] [Related]
12. In vivo nuclear uptake of a vitamin D analog (OCT) in different tumor cell populations of FA-6 cancer xenograft in nude mice by receptor autoradiography.
Koike N; Endo K; Kubodera N; Kumaki K; Ikeda K; Ogata E; Stumpf WE
Anticancer Res; 1999; 19(6B):4955-8. PubMed ID: 10697495
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional regulation of the parathyroid hormone-related peptide gene by glucocorticoids and vitamin D in a human C-cell line.
Ikeda K; Lu C; Weir EC; Mangin M; Broadus AE
J Biol Chem; 1989 Sep; 264(27):15743-6. PubMed ID: 2777759
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid on parathyroid hormone-related protein expression by oral cancer cells (HSC-3).
Abe M; Akeno N; Ohida S; Horiuchi N
J Endocrinol; 1998 Feb; 156(2):349-57. PubMed ID: 9518882
[TBL] [Abstract][Full Text] [Related]
15. DNA sequences in the rat parathyroid hormone-related peptide gene responsible for 1,25-dihydroxyvitamin D3-mediated transcriptional repression.
Falzon M
Mol Endocrinol; 1996 Jun; 10(6):672-81. PubMed ID: 8776727
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE.
Sepulveda VA; Weigel NL; Falzon M
Steroids; 2006 Feb; 71(2):102-15. PubMed ID: 16243370
[TBL] [Abstract][Full Text] [Related]
17. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
Brown AJ; Ritter CR; Finch JL; Morrissey J; Martin KJ; Murayama E; Nishii Y; Slatopolsky E
J Clin Invest; 1989 Sep; 84(3):728-32. PubMed ID: 2760211
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer cell type-specific regulation of the human PTHrP gene via a negative VDRE.
Tovar Sepulveda VA; Falzon M
Mol Cell Endocrinol; 2003 Jun; 204(1-2):51-64. PubMed ID: 12850281
[TBL] [Abstract][Full Text] [Related]
19. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer.
El Abdaimi K; Papavasiliou V; Rabbani SA; Rhim JS; Goltzman D; Kremer R
Cancer Res; 1999 Jul; 59(14):3325-8. PubMed ID: 10416587
[TBL] [Abstract][Full Text] [Related]
20. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
